Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA

Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA

• Late-Breaking Randomized Clinical Trial Data to be presented by Professor Isabel Deisenhofer, German Heart Center Munich Department of Electrophysiology
• Demonstration of Volta AF-Xplorer™ at Heart Rhythm Society (HRS) 2024, May 16-19
•  Dr. Andrea Natale, a world recognized leader in the field of electrophysiology, to moderate Rhythm Theater

Marseille (France), April 18, 2024 – Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in assessing complex cardiac arrhythmias such as atrial fibrillation (AF), today announced presentations to be made at the Heart Rhythm Society 2024 meeting in Boston, MA, USA, from May 16 to 19. In-person attendance and live online participation in a hybrid format will be available. Professor Isabel Deisenhofer, German Heart Center Munich Department of Electrophysiology will present late breaking data from the Volta TAILORED-AF clinical trial. Additionally, Volta will host a demonstration of Volta AF-Xplorer™ and a Rhythm Theater featuring a panel of experts in the field moderated by Dr. Andrea Natale, a leading cardiac electrophysiologist at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX, USA.

Summary of Presentations:

Volta’s AF-Xplorer™ identifies and annotates unique abnormalities (spatiotemporal dispersed electrograms) on 3D anatomical and electrical maps of the heart. This AI companion technology may help electrophysiologists to optimize catheter-ablation procedures for complex arrhythmias, including persistent AF.

Professor Isabel Deisenhofer will share findings from the TAILORED-AF clinical trial. The clinical trial is a transatlantic, multicenter, randomized, controlled study designed to determine if a tailored AI software-guided ablation strategy targeting areas of dispersion in combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation strategy targeting PVI alone for the treatment of persistent AF. TAILORED-AF was conducted in 26 sites and five countries.

Volta Medical is hosting a Rhythm Theater presentation, “The Future of AI Implementation in AF Ablation Procedures”. It will be moderated by Dr. Andrea Natale with a panel featuring Dr. Dhanunjaya “DJ” Lakkireddy (Kansas City Heart Rhythm Institute), Dr. Stavros Mountantonakis (Northwell Health, New York), Dr. Smit Vasaiwala (Loyola University Medical Center, Maywood), and Dr. Jean Paul Albenque (Clinique Pasteur, Toulouse).  This will be a comprehensive look at how intra-operative AI solutions can greatly enhance the physician’s assessment of complex AF, of which AF-Xplorer™ is one of the first examples in electrophysiology (EP).

Volta Medical will exhibit at booth #328, featuring a demonstration of the Volta AF-Xplorer™ software, while a tech suite at #TS266 will spotlight the company’s product vision. In addition, the company will present the poster: “Multi-Pronged Communication And Storage Platform For The Collection, Curation And Annotation Of Per-Procedural Cardiac Electrophysiology Datasets”. The poster discusses a ‘first of its kind’ data collection and enrichment ecosystem that greatly simplifies machine learning training and management in the data rich EP environment. Co-founder and CEO Théophile Mohr Durdez will be participating in the HRX Innovation Panel to discuss the challenges of bringing groundbreaking opportunities to market.

About Atrial Fibrillation

The American Heart Association (AHA) defines atrial fibrillation (AF) as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.¹ Approximately 33 million patients worldwide are living with AF.^2,3 Even though untreated AF doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition.

About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data. The company’s solution, AF-Xplorer™, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms, known as dispersed EGMs. AF-Xplorer™ is CE marked and FDA cleared. For more information, visit the company’s website at www.volta-medical.com.

Media Contact
Jeff Martin, SVP of Global Marketing
Volta Medical
jeffrey.martin@volta-medical.com

European Media Contact
Brittney Sojeva
MC Services AG
Volta-medical@mc-services.eu

References
____________________

1. https://www.heart.org/en/health-topics/atrial-fibrillation [last accessed June 9, 2023]
2. Colilla S, Crow A, Petku W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112:1142–1147. DOI: 10.1016/j.amjcard.2013.05.063
3. https://kompetenznetz-vorhofflimmern.de/en [last accessed June 9, 2023]